Introduction
Salvage radical prostatectomy after primary radiation failure remains a technically challenging intervention even in experienced hands and is associated with a high complication rate. 1 Minimally invasive techniques such a targeted cryoablation may be considered as a feasible alternative treatment. Fortunately, in most patients with recurrent prostate cancer the tumor cells have a relatively slow growth based on tumor biology, and thus the urologic oncologist still has sufficient time in order to perform a salvage procedure before the development of metastases.
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Case report
A 75-year-old man was referred for a second opinion regarding recurrent prostate cancer after radiation therapy. His initial prostate cancer was detected in 1994 by routine screening with a PSA of 6 ng/ml and a negative digital rectal examination. He underwent a biopsy that demonstrated a multifocal Gleason score 3 þ 4 ¼ 7 cancer. The patient elected brachytherapy and underwent implantation of 49 needles with 90 seeds of palladium-103 ( 103 Pd) of 1.3 millicuries to achieve a dose 11.5 Gy. He did well for almost 10 years with a stable PSA o1 ng/ml. He had a sudden rise in his PSA to 2.9 ng/ml in August 2003 and later to 4.8 ng/ml in 2004. He underwent multiple core biopsies demonstrating a recurrent Gleason Score 3 þ 4 ¼ 7 adenocarcinoma at the right base and in the right seminal vesicle (SV). Transrectal ultrasonography showed a 12.3 cm 3 prostate gland and some enlargement of the right SV (Figure 1a , b). A pelvic MRI confirmed a slight enlarged right SV and an intact prostate capsule. ProstaScintt scan (Cytogen Corp., Princeton, NJ) and bone scan were negative for local recurrence and metastatic disease. Past medical history included insulin dependent diabetes mellitus, erectile dysfunction, coronary artery disease status post myocardial infarction and peripheral vascular disease status post bilateral carotid endarterectomies.
The patient elected salvage cryoablation. Third generation cryotechnology (Oncura Inc., Plymouth Meeting, PA) using a helium/argon system and 17-G ultrathin cryoneedles were used. The whole prostate and adjacent right SV were aggressively ablated with a double freezethaw cycle (Figure 2a, b) . Two thermocouplers were inserted into the external urethral sphincter and Denonvillers' fascia to monitor temperatures. The critical level for tumor cryoablation below À401C was achieved during two cycles of freezing. The freezing process was stopped when the advancing edge of the iceball abuts the anterior rectal wall on ultrasound. The first thaw was performed actively using helium gas, and the second thaw was performed passively. The probes were removed and the patient was discharged on the next day. At 1 year after the procedure, he is asymptomatic without complication and has a PSA level of 0.1 ng/ml.
Discussion
According to data in the literature, approximately onethird of patients failing radiotherapy with well defined local recurrence may be ideal candidates to undergo potentially curative salvage radical prostatectomy. [1] [2] [3] [4] [5] [6] [7] [8] [9] This is because the rest (2/3) of patients already have extraprostatic disease. Under these circumstances the main problem is that diagnostic modalities such a transabdominal imaging, serum markers and routine prostate biopsy are not precise enough to distinguish between clinically localized and extraprostatic disease. [2] [3] [4] In this case, we demonstrate that SV involvement may also be one of the important indicators of local recurrence after radiation failure. Therefore, we recommend SV biopsies on each side in addition to multicore biopsies of the prostate.
In general, salvage radical prostatectomy after primary radiation therapy failure has been more technically challenging than primary radical prostatectomy.
1-2 In a recent review article, Touma et al. 4 summarized the data from the English literature demonstrating a mean rate of major complications for salvage radical prostatectomy as follows: estimated blood loss -992 cm 3 , operative time -3.7 h, rectal injury -6.6%, bladder neck contracture -18%, incontinence -45% and SV involvement -from 29 to 63%. Scardino's group revealed in their study that previous radiotherapy caused extensive pelvic scarring and virtually all patients were impotent after salvage radical prostatectomy with overall potency results at 5 years as 16%. 5 Not surprisingly only 25% of surveyed urologists and radiation oncologists would recommend salvage radical prostatectomy to a patient aged 45-65 years with presumed local recurrence after radiation therapy. 6 The introduction of third-generation cryotechnology (Oncura Inc., Plymouth Meeting, PA) using 17-guage ultrathin cryoneedles and an argon-helium gas system, and recent modifications in the technique of salvage cryoablation have enabled cryosurgeons to treat these tumors safely and with significantly decreased morbidity. [10] [11] [12] [13] [14] [15] [16] [17] The results of a large database (963 patients) after primary and salvage procedures from Allegheny General Hospital (AGH) demonstrated 10-year undetectable PSA -response to salvage cryoablation as approximately 60%, that is, comparable to the results of salvage radical prostatectomy. 13 Furthermore, Cohen demonstrated the rate of certain complications has dramatically decreased with time due to improvements in technology and techniques when comparing first and second versus third-generation equipment: urethral sloughing (from 14 to 2%), incontinence (from 3.2 to 0%), and prostate stones (from 4 to 0%), respectively. 13 Katz et al. 11 recently presented their 10-year experience of salvage cryoablation for 157 patients failing radiation showing that 83.4% of patients had PSA nadir o1.0 ng/ml with significantly less complications than after salvage radical prostatectomy. Patients in this series had a relatively low rate of morbidities including incontinence (9.7%), voiding complications (5.8%), rectal pain (12.8%), and retention (1.9%). The 50 most recently treated patients had a 83.3% ASTRO defined biochemical recurrence free survival and 6.4% incontinence rate. 11 Ultimately, we would expect that similar to salvage radical prostatectomy series, salvage cryoablation can successfully treat 1/3 patients who still have organconfined disease. In order to improve patient selection, we need to do a better job with restaging after radiation along two fronts: (1) a more thorough evaluation using all available (imaging, clinical, and molecular) modalities such as endorectal coil MRI or MR spectroscopic imaging, ProstaScintt, bone scan, biopsy of prostate, and SVs in additional to clinical stage and PSA nadir, and (2) introduction better molecular markers and advanced imaging in the future.
The presented case illustrates a man with radiorecurrent prostate cancer in the base of the prostate and adjacent right SV. Although it is techniqually possible to freeze the SV, we are not advocating that cryotherapy can cure all patients with SV involvement. Rather, if one has a finite amount of prostate cancer extension into the adjacent SV in the absence of systemic disease, the cryosurgeon can safely freeze that portion of the SV adjacent to the prostate.
Conclusion
The efficacy of salvage radical prostatectomy and cryoablation should be similar, if patients are well selected based on thorough preoperative staging. However, outpatient prostate cryotherapy has several advantages including its minimally invasive character that is better tolerated by patients with lower complications. We need to continue to improve our patient selection of appropriate candidates who can likely be cured with salvage procedures.
